Minerva Neurosciences
NERV
82 hedge funds and large institutions have $261M invested in Minerva Neurosciences in 2017 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 39 increasing their positions, 15 reducing their positions, and 9 closing their positions.
336% more call options, than puts
Call options by funds: $941K | Put options by funds: $216K
160% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 15
122% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 9
27% more capital invested
Capital invested by funds: $205M → $261M (+$55.4M)
15% more funds holding
Funds holding: 71 → 82 (+11)
1.05% more ownership
Funds ownership: 8.98% → 10.03% (+1%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$10.5M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$9.4M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.5M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.83M |
| 5 |
JGC
J. Goldman & Co
New York
|
+$3.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$6.57M |
| 2 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$5.34M |
| 3 |
O
OrbiMed
New York
|
-$2.91M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.51M |
| 5 |
NC
Nexthera Capital
New York
|
-$1.47M |
NERV Hedge Fund Activity: Q2 2017 in Review
82 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Minerva Neurosciences (NERV) for Q2 2017, worth a combined $261M — up 27% from $205M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new NERV positions and 9 closed out — a net gain of 11 holders — while 39 added to existing stakes and 15 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $10.5M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $6.57M sold.
- 82 institutional investors held Minerva Neurosciences (NERV) as of Q2 2017, up from 71 in Q1 2017.
- Funds reported $261M of Minerva Neurosciences stock for Q2 2017, up 27% quarter-over-quarter.
- 20 funds opened new Minerva Neurosciences positions in Q2 2017 and 9 closed out, a net change of +11 holders.
- The largest Minerva Neurosciences buyer in Q2 2017 was T. Rowe Price Associates, an estimated $10.5M added.
- The largest Minerva Neurosciences seller in Q2 2017 was Perceptive Advisors, an estimated $6.57M sold.
Based on aggregated 13F filings for Q2 2017.